Royalty Pharma Acquires Interest In Agios Pharmaceuticals' Royalty On Servier's Vorasidenib For $905M In Upfront CashUpon FDA Approval Of Vorasidenib
Portfolio Pulse from Benzinga Newsdesk
Royalty Pharma has acquired an interest in Agios Pharmaceuticals' royalty on Servier's Vorasidenib for $905 million in upfront cash, contingent upon FDA approval of Vorasidenib.
May 28, 2024 | 11:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agios Pharmaceuticals has sold its royalty interest in Servier's Vorasidenib to Royalty Pharma for $905 million in upfront cash, contingent upon FDA approval of Vorasidenib.
The sale of royalty interest provides Agios Pharmaceuticals with significant upfront cash, which could be used for further R&D or other strategic initiatives.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Royalty Pharma has acquired an interest in Agios Pharmaceuticals' royalty on Servier's Vorasidenib for $905 million in upfront cash, contingent upon FDA approval of Vorasidenib.
The acquisition of royalty interest in Vorasidenib could potentially enhance Royalty Pharma's revenue streams, especially if the drug receives FDA approval.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100